Mode
Text Size
Log in / Sign up

Meta-analysis identifies rare gene-trait associations across 1.2 million individuals in global biobanks

Meta-analysis identifies rare gene-trait associations across 1.2 million individuals in global…
Photo by digitale.de / Unsplash
Key Takeaway
Note that cross-ancestry meta-analysis detects rare gene-trait associations missed by individual biobanks.

This publication is a meta-analysis reviewing gene-based data from over 1.2 million individuals across diverse ancestries within global biobanks and cohorts. The scope includes 33 clinical endpoints and 11 quantitative traits to identify gene-trait associations related to asthma, chronic obstructive pulmonary disease, and type 2 diabetes. The study does not report adverse events or discontinuations.

The authors identified 514 gene-trait associations in total. They found that 36.1% of gene-level associations were undetectable in any individual biobank. Additionally, 91 associations emerged only through cross-ancestry meta-analysis. At the variant level, 25.0% of phenotype-locus associations were detectable only through meta-analysis.

Effect size estimates across ancestries correlated with concordant directions of effect. The study establishes a scalable framework and freely available community resource for rare variant meta-analysis across global biobanks. Limitations regarding funding or conflicts were not reported. The practice relevance focuses on establishing this framework rather than prescribing specific clinical interventions.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Rare coding variants can have large effects on disease risk and provide direct routes from human genetics to disease mechanisms and therapeutic targets, but their discovery is constrained by sample size, particularly for low-prevalence diseases. Here we establish the Biobank Rare Variant Analysis (BRaVa) consortium, a global rare variant association resource that integrates sequencing and linked health-record data from ten biobanks and cohorts comprising over 1.2 million individuals across diverse ancestries. We performed gene-based meta-analyses of rare coding variation across 33 clinical endpoints and 11 quantitative traits. Aggregating evidence across biobanks and ancestries identified 514 gene-trait associations, including 31 not previously reported in prior studies or curated association resources following systematic literature review. Notably, 36.1% of gene-level associations were undetectable in any individual biobank, and 91 emerged only through cross-ancestry meta-analysis, demonstrating that federated integration enables discovery beyond the reach of single cohorts. Similar gains were observed at the variant level, where 25.0% of phenotype-locus associations were detectable only through meta-analysis. Effect size estimates were correlated across ancestries with concordant directions of effect, supporting the generalizability of rare variant associations. The identified signals implicate pathways involved in transcriptional and epigenetic regulation, metabolism, vascular and epithelial biology, and immune function, highlighting rare coding variation as an engine for biological discovery across medical record phenotypes. For example, damaging variation in ANKRD12 implicates inflammatory transcriptional dysregulation in asthma and chronic obstructive pulmonary disease, and ultra-rare predicted loss-of-function variants in NAA15 link protein acetylation processes to type 2 diabetes risk. BRaVa establishes a scalable framework and freely available community resource for rare variant meta-analysis across global biobanks. Public release of gene- and variant-level association summary statistics provides a reference map of rare coding variant associations to support disease gene discovery, biological interpretation, and therapeutic target prioritization as sequencing-linked health-record resources continue to expand.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.